| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $70.0M | — | +23.8% |
| SG&A Expense | $17.3M | — | +16.9% |
| Operating Income | -$87.3M | — | -22.3% |
| Net Income | -$83.0M | — | -21.6% |
| EPS (Basic) | -$2.46 | — | +90.9% |
| EPS (Diluted) | -$2.46 | — | +90.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $161.2M | +53.6% | -21.2% |
| Short-term Investments | $351.0M | +51.9% | — |
| Current Assets | $529.5M | +51.8% | — |
| Total Assets | $850.8M | +43.1% | — |
| Current Liabilities | $45.1M | -18.1% | — |
| Total Liabilities | $300.2M | -3.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$89.8M | — | -64.7% |
| Capital Expenditures | $262K | — | -98.8% |
| Investing Cash Flow | -$203.2M | — | +5.0% |
| Financing Cash Flow | $349.3M | — | -0.3% |
| Free Cash Flow | -$90.1M | — | -17.1% |
| — |
| Stockholders' Equity | $550.7M | +162.6% | +186.0% |